EpiBiome advances funding to support phage therapy

EpiBiome secures $6m Series A financing to develop alternatives to small-molecule antibiotics for ag.

EpiBiome, a precision microbiome engineering company, announced Feb. 4 that it has completed a $6 million Series A financing.

Participating in the round were several leading next-generation sequencing investors, including Viking Global Investors via the Illumina Accelerator Boost Capital, Matrix Capital Management, Alexandria Venture Investments, SV Tech Ventures and China Rock Capital Management. Proceeds from the financing will be used to develop alternatives to small-molecule an

All access premium subscription

This content requires a subscription to Feedstuffs in order to access. If you are a paid subscriber, use your email and password to Log In now.


Current Feedstuffs Subscribers: Online and mobile access are now included at no charge to you. To read this article, use your subscriber email and password to log-in to your account (or contact us for assistance in updating your account.)


Not Currently a Subscriber: Subscribe NOW to Feedstuffs and receive our print and/or digital publications, enewsletters and premium online content. Visit Feedstuffs.com and click on Subscribe at the top of the page for more information.


SUBSCRIBE NOW https://circulation.feedstuffs.com/Publications.aspx


TO RENEW YOUR SUBSCRIPTION https://circulation.feedstuffs.com/SubscriptionOffers.aspx


Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish